Patrys Ltd (ASX: PAB) Share Price and News

Price

$0.001

Movement

0.00 (0.0)

as at 24 Jun - Closed (20 mins delayed)

52 Week Range

$0.001 - $0.008

 
1 Year Return

-85.71%

Patrys Ltd Chart and Price Data

2025
2025
2025
2025
$0.00
$0.003
$0.005
$0.00
$0.003
$0.005
$0.00
$0.003
$0.005
$0.00
$0.003
$0.005

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $2.37 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.37 billion
Earnings per share -0.001
Dividend per share N/A
Year To Date Return -75.00%
Earnings Yield N/A
Franking -
Share Price

$0.001

Day Change

0.00 (0.0)

52 Week Range

$0.001 - $0.008

Yesterday's Close

$0.001

Today's Open

$0.001

Days Range

$0.001 - $0.001

Volume

171,160

Avg. Volume (1 month)

3,044,715

Turnover

$171

as at 24 Jun - Closed

  • Patrys Ltd (ASX: PAB)
    Latest News

    a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.
    Healthcare Shares

    Here's why the Patrys (ASX:PAB) share price is tumbling 16% today

    Investors tend to keep a keen eye on clinical trial progress.

    Read more »

    A medical researcher in a white coat holds laboratory equipment and smiles.
    Share Market News

    Here's why the Patrys (ASX: PAB) share price is climbing 13% today

    This small-cap ASX share revealed some exciting news today.

    Read more »

    ASX shares fund manager martin hickson
    Ask a Fund Manager

    Why we avoid mining and biotech ASX shares: fund manager

    Ask A Fund Manager: 1851 Capital's Martin Hickson also reveals the telecommunications company that gets paid to build its products.

    Read more »

    PAB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    23rd Jun 2025 2025-06-23T16:48:53 Notification of cessation of securities - PABYesNo4:48pm413k
    23rd Jun 2025 2025-06-23T16:47:28 Final Director's Interest Notices x2YesNo4:47pm4788k
    23rd Jun 2025 2025-06-23T16:43:38 Initial Director's Interest Notices x2YesNo4:43pm4617k
    18th Jun 2025 2025-06-18T09:40:07 Section 708A Cleansing StatementYesNo9:40am2275k
    18th Jun 2025 2025-06-18T09:29:02 Application for quotation of securities - PABYesNo9:29am616k
    17th Jun 2025 2025-06-17T09:35:34 Proposed issue of securities - PABYesNo9:35am516k
    17th Jun 2025 2025-06-17T09:32:34 Deed of Release entered into with CEOYesNo9:32am1219k
    10th Jun 2025 2025-06-10T17:47:00 Reinstatement to Official QuotationYesNo5:47pm1104k
    10th Jun 2025 2025-06-10T17:46:50 Proposed issue of securities - PABYesNo5:46pm619k
    10th Jun 2025 2025-06-10T17:46:44 Proposed issue of securities - PABYesNo5:46pm620k

    About Patrys Ltd

    Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.

    PAB Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    23 Jun 2025 $0.00 $0.00 0.00% 863,380 $0.00 $0.00 $0.00
    20 Jun 2025 $0.00 $0.00 0.00% 2,318,106 $0.00 $0.00 $0.00
    19 Jun 2025 $0.00 $0.00 0.00% 1,575,000 $0.00 $0.00 $0.00
    18 Jun 2025 $0.00 $0.00 0.00% 1,288,770 $0.00 $0.00 $0.00
    17 Jun 2025 $0.00 $0.00 0.00% 1,580,000 $0.00 $0.00 $0.00
    16 Jun 2025 $0.00 $0.00 0.00% 380,326 $0.00 $0.00 $0.00
    13 Jun 2025 $0.00 $0.00 0.00% 2,748,021 $0.00 $0.00 $0.00
    12 Jun 2025 $0.00 $0.00 0.00% 2,591,022 $0.00 $0.00 $0.00
    11 Jun 2025 $0.00 $0.00 0.00% 43,052,603 $0.00 $0.00 $0.00
    29 May 2025 $0.00 $0.00 0.00% 2,500,000 $0.00 $0.00 $0.00
    28 May 2025 $0.00 $0.00 0.00% 1,750,000 $0.00 $0.00 $0.00
    27 May 2025 $0.00 $0.00 0.00% 247,068 $0.00 $0.00 $0.00

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 Dec 2024 James Campbell Expiry 11,000,000 $44,000
    Options expired.
    18 Dec 2024 Michael Stork Expiry 800,000 $3,200
    Options expired.
    18 Dec 2024 Pamela Klein Expiry 800,000 $3,200
    Options expired. As per announcement on 24-12-2024

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr James Campbell Chief Executive OfficerManaging Director Nov 2014
    Dr. Campbell has over 30 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of Australian and international biotechnology companies. Dr. Campbell was previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX: CXS), where, as a member of the executive team he helped transform a research based company with a market capitalization of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011 ChemGenex was sold to Cephalon for $230M. Dr. Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. Dr Campbell chairs the board of Australia's peak industry body for biotechnology, AusBiotech.
    Mr Peter James Christie Non-Executive ChairmanNon-Executive Director Jun 2025
    Mr Christie has served on the boards of several public companies in the resource sector since 2006 and has developed interests in hospitality and property development.
    Mr. Christie is the Director of Hawkins Christie Management Services, a firm based in Nedlands,
    Western Australia, providing accounting and management services. He is also the current President of the South Fremantle Football Club, a role he has held since 2018, following over a decade of service on the club's board. His leadership has been instrumental in the club's strategic growth and community engagement initiatives.
    Dr Anton Uvarov Non-Executive Director Jun 2025
    Dr. Anton Uvarov has experience in the healthcare sector, with a particular focus on
    neuroscience. He began his career in biotechnology investment as an equities analyst at Citigroup and
    has since co-founded and served as a director of several ASX-listed companies, including clinical-stage
    ventures such as Dimerix (ASX:DXB) and Actinogen Medical (ASX:ACW).
    Dr. Uvarov is currently a Non-Executive Director of Neuroscientific Biopharmaceuticals (ASX:NSB), and
    previously served on the board of Imugene (ASX:IMU), a late-stage clinical oncology company. Dr.
    Uvarov is also the Executive Director and co-founder of BlinkLab (ASX:BB1), a digital diagnostics
    company focused on autism.
    Mr Stefan Ross Company Secretary Oct 2021
    Mr Ross has over 10 years of experience in accounting and secretarial services for ASX listed companies. His experience includes ASX compliance, corporate governance control and implementation, statutory financial reporting, shareholder meeting requirements, capital raising management, and board and secretarial support.
    Rebecca Tunstall Vice President Corporate Development
    -
    Valentina Dubljevic Vice President Research & Development
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr Dax Marcus Calder 129,000,000 6.27%
    Citicorp Nominees Pty Limited 99,195,175 4.82%
    Stork Holdings 2010 Ltd 98,773,814 4.80%
    Dax Calder Pty Ltd 65,000,000 3.16%
    Mr Mladen Marusic 59,680,843 2.90%
    Kemast Investments Pty Ltd <Km Stokes S/F No 1 A/C> 39,814,272 1.94%
    Estelleanne Pty Ltd 35,500,000 1.73%
    Marginata Pty Ltd <Roy Bolton Super Fund A/C> 31,000,000 1.51%
    Altum Trustees Limited <Mk Pension Plan-473278 A/C> 28,049,888 1.36%
    Staffwear Pty Ltd <Dax Calder Super Fund A/C> 27,000,000 1.31%
    Altum Trustees Ltd <The Konda Family A/C> 26,499,994 1.29%
    Towns Corporation Pty Ltd <PAE Family A/C> 21,715,000 1.06%
    Mr Vinh Tran 21,513,277 1.05%
    Mr Justin Frank Puddick 19,000,000 0.92%
    Yale University 16,116,324 0.78%
    Edstop Pty Limited <Superannuation Fund A/C> 15,501,223 0.75%
    Mr Craig Geoffrey Thomas 13,439,814 0.65%
    Mr Benjamin John Wagner 13,280,000 0.65%
    Mr Vishal Gumber 12,933,733 0.63%
    Mr Thomas Edgar Edmunds and Mrs Susan Rae Edmunds <The Edmunds Family S/F A/C> 11,500,000 0.56%

    Profile

    since

    Note